<DOC>
	<DOCNO>NCT00037401</DOCNO>
	<brief_summary>To compare effect statin therapy alone statin plus fibrate therapy several emerge risk factor atherosclerotic cardiovascular disease representative subgroup ACCORD cohort follow cardiovascular endpoint .</brief_summary>
	<brief_title>Postprandial Lipemia Endothelial Function ACCORD- Ancillary ACCORD</brief_title>
	<detailed_description>BACKGROUND : The National Heart , Lung , Blood Institute-supported ACCORD trial use two connect 2x2 design test efficacy ( ) optimal glucose control ( HbA1c = 6.0 % ) versus standard control ( HbA1c + 7.5 % ) 10,000 patient type 2 diabetes mellitus , ( b ) intense systolic blood pressure control ( 120 mm Hg ) versus less intense control ( 140 mm Hg ) 4,200 patient , ( c ) combine low density lipoprotein cholesterol lowering , triglyceride lower , high density lipoprotein cholesterol raise versus low density lipoprotein cholesterol lower 5,800 patient . The primary outcome overall ACCORD trial combination non-fatal myocardial infarction , non-fatal stroke , cardiovascular death . The comparison lipid-altering therapy carry Lipid Arm ACCORD , 5,800 subject treat simvastatin , addition , randomly assign receive either fenofibrate placebo . The main ACCORD trial measure fast blood sample lipid , lipoprotein fraction , apolipoproteins . The ancillary study compare effect simvastatin plus fenofibrate effect simvastatin alone postprandial lipemia 250 ACCORD patient 4 site Northeast Network . The study response initiative Ancillary Studies Heart , Lung , Blood Disease Trials release June , 2000 . DESIGN NARRATIVE : The ancillary study compare effect simvastatin plus fenofibrate effect simvastatin alone postprandial lipemia 250 ACCORD patient 4 site Northeast Network . In addition , study compare effect two treatment strategy baseline postprandial endothelial function , marker coagulation , endothelial function , oxidative stress . The ancillary study provide unique opportunity determine possible mechanism whereby simvastatin plus fenofibrate therapy may associate reduce cardiovascular event overall ACCORD trial . The study divide three specific aim . Specific Aim A : To carry high fat load study postprandial lipemia patient participate Lipid Arm ACCORD trial compare postprandial excursion triglyceride , triglyceride-rich lipoprotein , retinyl palmitate , remnant lipoprotein cholesterol patient receive fenofibrate plus simvastatin postprandial excursion patient receive simvastatin . Specific Aim B : To determine brachial artery dilatation response increase blood flow post- forearm ischemia prior , five hour , ingestion high fat load two patient groups.and Specific Aim C : To determine baseline level PAI-1 , fibrinogen factor VII , postprandial excursion factor VII , sVCAM-1 , sICAM-1 , sE-selectin two patient group .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>No eligibility criterion</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>